Sign In
Buy CGEN
$2.19
-0.0700 (-3.10%)
At Close: Jun 03, 2026
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
07:00am, Tuesday, 18'th Feb 2025
HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced,
Compugen: Immuno-Oncology Innovator Poised For A Comeback
06:11am, Tuesday, 18'th Feb 2025
Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash an
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:00am, Tuesday, 04'th Feb 2025
HOLON, Israel , Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen initiated with bullish view at Oppenheimer, here's why
07:57am, Monday, 13'th Jan 2025
Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)
New approach to harness cytokine biology to treat cancer patients advances to the clinic First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gil
Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antib
Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript
03:35pm, Tuesday, 12'th Nov 2024
Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
12:05pm, Tuesday, 12'th Nov 2024
Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago.
Compugen Reports Third Quarter 2024 Results
07:00am, Tuesday, 12'th Nov 2024
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunothe
Compugen to Participate in Stifel 2024 Healthcare Conference
07:00am, Monday, 11'th Nov 2024
HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announce
HOLON, ISRAEL , Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
07:00am, Tuesday, 29'th Oct 2024
HOLON, Israel , Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
01:15pm, Thursday, 24'th Oct 2024
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
Compugen to Present New Clinical Data at SITC 2024
07:00am, Monday, 07'th Oct 2024
HOLON, Israel , Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced,
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 11'th Sep 2024
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
